1 completed. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow LY3022855: new trials by email Literature Review of LY3022855 trials Research Report on LY3022855
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma LY3022855, Vemurafenib, Cobimetinib - Melanoma | Phase 1 / Phase 2 | Completed | Dana-Farber Cancer Institute | 5 | 2017-06-06 | 2024-07-17 |
Melanoma (1)
Dana-Farber Cancer Institute (1)
United States (1)